A Phase 2 interventional study of Tofacitinib and Placebo in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 36 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-04-11.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 2, and was the 23rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 49th largest by enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2014, is one of 28 in phase 2, and was the 112th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
Drug: Tofacitinib
Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
Drug: Placebo
5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
Placebo tablets twice daily with background methotrexate for 12 weeks
Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 4
VZV-specific IgG levels as measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline (pre-vaccination; Day -14), Week 4 (6 weeks post-vaccination)
Fold Change From Baseline in VZV-Specific IgG Levels at Day 1 and Week 12
Time frame: Baseline (pre-vaccination; Day -14), Day 1 (2 weeks post-vaccination), Week 12 (14 weeks post-vaccination)
Absolute Values in VZV-Specific IgG Levels at Day 1, Week 4 and Week 12
The absolute geometric mean titer (GMT) of VZV-specific IgG levels was calculated from logarithmically transformed assay values.
Time frame: Day 1 (2 weeks post-vaccination), Week 4 (6 weeks post-vaccination), Week 12 (14 weeks post-vaccination)
Percentage of Participants With >=1.5 Fold Change in VZV-Specific IgG Levels Day 1, Week 4 and Week 12
VZV-specific IgG levels as measured by ELISA. A ratio greater than or equal to (\>=)1.5 was defined as a responder.
Time frame: Day 1 (2 weeks post-vaccination), Week 4 (6 weeks post-vaccination), Week 12 (14 weeks post-vaccination)
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 16 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
Time frame: Baseline up to Week 16
Number of Participants With Zoster Vaccine-Related AEs by System Organ Class
Zoster vaccine-related AEs included General Disorders and Administration Site Conditions (injection site erythema, pain, pruritis, rash, swelling; vaccination site erythema, pruritus, rash), Infections and Infestations (disseminated herpes zoster), and Musculoskeletal and Connective Tissue Disorders (myalgia). All zoster vaccine-related AEs were mild, except for the herpes zoster AE classified under Infections and Infestations, which was moderate in severity.
Time frame: Baseline up to Week 16
Number of Participants With Clinical Herpes Zoster Events by Severity
Clinical herpes is manifested as mild, moderate, or severe disseminated herpes zoster.
Time frame: Baseline up to Week 16
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Participants with the following abnormalities were discontinued from the study: 2 sequential absolute neutrophil counts (ANC) \<1000/mm\^3; 2 sequential hemoglobin values \<8.0 g/dL or decreases of \>30% from baseline value; 2 sequential absolute lymphocyte count \<500/mm\^3; 2 sequential platelet counts \<75,000/mm\^3; 2 sequential alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>=3 times the upper limit of normal (X ULN) with a total bilirubin value \>=2X ULN, elevated international normalized ratio (INR), or accompanied by signs/symptoms consistent with hepatic injury; 2 sequential ALT or AST elevations \>=5X ULN regardless of total bilirubin or accompanying symptoms; confirmed increases in serum creatinine (SCr) \>50% over the average of screening and baseline values; a confirmed positive urine pregnancy test or refusal to use appropriate contraception in a woman of childbearing potential.
Time frame: Baseline up to Week 16
| Milestone | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Started | 57 | 55 |
| Completed | 46 | 50 |
| Not completed | 11 | 5 |
| Withdrew: Adverse event | 9 | 4 |
| Withdrew: Lack of efficacy | 2 | 1 |
VZV-specific IgG levels as measured by enzyme-linked immunosorbent assay (ELISA).
| fold rise | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 4 | 1.736 (1.546 to 1.950) | 2.105 (1.871 to 2.369) |
| fold rise | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Day 1 | 1.947 (1.733 to 2.186) | 2.005 (1.782 to 2.256) |
| Week 12 | 1.496 (1.323 to 1.691) | 1.636 (1.448 to 1.847) |
The absolute geometric mean titer (GMT) of VZV-specific IgG levels was calculated from logarithmically transformed assay values.
| [gp]ELISA units/mL | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Day 1 | 361.603 (300.012 to 435.838) | 384.219 (317.477 to 464.993) |
| Week 4 | 322.486 (267.557 to 388.690) | 403.422 (333.343 to 488.232) |
| Week 12 | 278.599 (229.984 to 337.489) | 312.328 (257.319 to 379.096) |
VZV-specific IgG levels as measured by ELISA. A ratio greater than or equal to (\>=)1.5 was defined as a responder.
| percentage of participants | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Day 1 | 47.17 (37.66 to 56.85) | 55.56 (45.93 to 64.86) |
| Week 4 | 43.40 (34.06 to 53.13) | 57.41 (47.77 to 66.61) |
| Week 12 | 43.18 (32.90 to 53.96) | 45.83 (35.87 to 56.07) |
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 16 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
| participants | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| AEs | 21 | 16 |
| SAEs | 0 | 3 |
Zoster vaccine-related AEs included General Disorders and Administration Site Conditions (injection site erythema, pain, pruritis, rash, swelling; vaccination site erythema, pruritus, rash), Infections and Infestations (disseminated herpes zoster), and Musculoskeletal and Connective Tissue Disorders (myalgia). All zoster vaccine-related AEs were mild, except for the herpes zoster AE classified under Infections and Infestations, which was moderate in severity.
| participants | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| General and Administration Site Conditions | 2 | 4 |
| Infections and Infestations | 0 | 1 |
| Musculoskeletal and Connective Tissue Disorders | 0 | 1 |
Clinical herpes is manifested as mild, moderate, or severe disseminated herpes zoster.
| participants | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Mild Herpes Zoster | 0 | 0 |
| Moderate Herpes Zoster | 0 | 1 |
| Severe Herpes Zoster | 0 | 0 |
Participants with the following abnormalities were discontinued from the study: 2 sequential absolute neutrophil counts (ANC) \<1000/mm\^3; 2 sequential hemoglobin values \<8.0 g/dL or decreases of \>30% from baseline value; 2 sequential absolute lymphocyte count \<500/mm\^3; 2 sequential platelet counts \<75,000/mm\^3; 2 sequential alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>=3 times the upper limit of normal (X ULN) with a total bilirubin value \>=2X ULN, elevated international normalized ratio (INR), or accompanied by signs/symptoms consistent with hepatic injury; 2 sequential ALT or AST elevations \>=5X ULN regardless of total bilirubin or accompanying symptoms; confirmed increases in serum creatinine (SCr) \>50% over the average of screening and baseline values; a confirmed positive urine pregnancy test or refusal to use appropriate contraception in a woman of childbearing potential.
| participants | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Laboratory Parameters | 1 | 0 |
Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Twice a Day | — | 0/57 (0%) | 9/57 (15.8%) |
| Tofacitinib 5 mg Twice a Day | — | 3/55 (5.5%) | 6/55 (10.9%) |
| Event | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Bile duct stoneHepatobiliary disorders | 0/57 | 1/55 |
| CholangitisHepatobiliary disorders | 0/57 | 1/55 |
| BronchitisInfections and infestations | 0/57 | 1/55 |
| Herpes zoster disseminatedInfections and infestations | 0/57 | 1/55 |
| Event | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 9/57 | 3/55 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/57 | 3/55 |
The baseline analysis population included all randomized participants who received at least 1 dose of study drug (tofacitinib or placebo).
| Age, Continuous(years) | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day | Total |
|---|---|---|---|
| Mean | 62.0 ± 8.7 | 61.7 ± 6.2 | 61.8 ± 7.6 |
| Sex: Female, Male(Participants) | Placebo Twice a Day | Tofacitinib 5 mg Twice a Day | Total |
|---|---|---|---|
| Female | 38 | 42 | 80 |
| Male | 19 | 13 | 32 |
Ran from Jun 2014 to primary completion in Jun 2015, 12 months.
Results were first posted in Apr 2018, 2 years 10 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 12 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib